Skip to main content
Article thumbnail
Location of Repository

Docosahexaenoic Acid Inhibits Helicobacter pylori Growth In Vitro and Mice Gastric Mucosa Colonization

By Marta Correia, Valérie Michel, António A. Matos, Patrícia Carvalho, Maria J. Oliveira, Rui M. Ferreira, Marie-Agnès Dillies, Michel Huerre, Raquel Seruca, Ceu Figueiredo, Jose C. Machado and Eliette Touati


H. pylori drug-resistant strains and non-compliance to therapy are the major causes of H. pylori eradication failure. For some bacterial species it has been demonstrated that fatty acids have a growth inhibitory effect. Our main aim was to assess the ability of docosahexaenoic acid (DHA) to inhibit H. pylori growth both in vitro and in a mouse model. The effectiveness of standard therapy (ST) in combination with DHA on H. pylori eradication and recurrence prevention success was also investigated. The effects of DHA on H. pylori growth were analyzed in an in vitro dose-response study and n in vivo model. We analized the ability of H. pylori to colonize mice gastric mucosa following DHA, ST or a combination of both treatments. Our data demonstrate that DHA decreases H. pylori growth in vitro in a dose-dependent manner. Furthermore, DHA inhibits H. pylori gastric colonization in vivo as well as decreases mouse gastric mucosa inflammation. Addition of DHA to ST was also associated with lower H. pylori infection recurrence in the mouse model. In conclusion, DHA is an inhibitor of H. pylori growth and its ability to colonize mouse stomach. DHA treatment is also associated with a lower recurrence of H. pylori infection in combination with ST. These observations pave the way to consider DHA as an adjunct agent in H. pylori eradication treatment

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2003). A
    2. (2007). A reproducible scoring system for quantification of histologic lesions of inflammatory disease in mouse gastric epithelium.
    3. (1988). A sharper Bonferroni procedure for multiple tests of significance.
    4. (1997). A standardized mouse model of Helicobacter pylori Infection: Introducing the Sydney Strain.
    5. (1985). Antibiotic-like action of essential fatty acids.
    6. (2002). Bactericidal effects of fatty acids and monoglycerides on Helicobacter pylori.
    7. (2006). Characterization of Helicobacter pylori Lytic Transglycosylases Slt and MltD.
    8. (1997). Clarification of the link between polyunsaturated fatty acids and Helicobacter pylori-associated duodenal ulcer disease: a dietary intervention study.
    9. (2011). Core Team
    10. (2007). Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report.
    11. (2007). Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men.
    12. (2000). Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
    13. (2000). European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori.
    14. (2007). Gastric cancer risk and erythrocyte composition of Docosahexaenoic acid with anti-inflammatory effects.
    15. (2001). Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses.
    16. (2006). Helicobacter pylori treatment: a practical approach.
    17. (2010). In vivo and in vitro effect of a nutrient mixture on a human hepatocarcinoma cell line SKHEP-1.
    18. (1977). Inactivation and inhibition of replication of the enveloped bacteriophage by fatty acids.
    19. (1994). Inhibition effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration.
    20. (1998). Labigne A
    21. (2001). Lobo A
    22. (1986). Melly A
    23. (1996). Morphological conversion of Helicobacter pylori from bacillary to coccoid form.
    24. (2002). Pathogenesis of Helicobacter pylori infection. Helicobacter 7(sup):
    25. (1989). Prostaglandins can modify gammaradiation and chemical-induced cytotoxicity and genetic damage both in vitro and in vivo.
    26. (1987). Protection of the gastric mucosa by linoleic acid - a nutrient essential fatty acid.
    27. (2003). Roberton A
    28. (2011). Stress responses: the contribution of prostaglandin E(2) and its receptors.
    29. (1957). Studies of intestinal digestion and absorption in the human.
    30. (2003). Surveillance de la re ´sistance de Helicobacter pylori aux antibiotiques. In: Surveillance nationale des maladies infectieuses 1998–2000. St Maurice, France: Institut de Veille Sanitaire.
    31. (1996). Susceptibility of Helicobacter pylori to bactericidal properties of medium chain monoglycerides and free fatty acids.
    32. (2002). Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs; results of a double-blind, randomized, multicenter, active and placebo controlled study of misoprostol vs lansoprazole.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.